Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression

References

• Jain P, Das VNR, Ranjan A, Chaudhary R, Pandey K. Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. J Res Pharm Pract 2013; 2:156-61; PMID:24991625; http://dx.doi.org/10.4103/2279-042X.128145
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30; PMID:26742998; http://dx.doi.org/10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther 2015; 9:773; PMID:25709401; http://dx.doi.org/10.2147/DDDT.S80207
   PubMed Web of Science ®Google Scholar
• Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph+ ALL–role of ponatinib. Biologics 2014; 8:243-54; http://dx.doi.org/10.2147/BTT.S50734
   PubMedGoogle Scholar
• Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships. Blood 2013; 121:489-98; PMID:23223358; http://dx.doi.org/10.1182/blood-2012-05-431379
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122:872-84; PMID:23803709; http://dx.doi.org/10.1182/blood-2013-05-501569
   PubMed Web of Science ®Google Scholar
• Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol 2015; 94 Suppl 2:S141-7; PMID:25814080; http://dx.doi.org/10.1007/s00277-015-2322-2
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-37; PMID:15914554; http://dx.doi.org/10.1182/blood-2005-03-1036
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014; 26:428-42; PMID:25132497; http://dx.doi.org/10.1016/j.ccr.2014.07.006
   PubMed Web of Science ®Google Scholar
• Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009; 114:2598-605; PMID:19625707; http://dx.doi.org/10.1182/blood-2008-08-173674
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141:1117-34; PMID:20602996; http://dx.doi.org/10.1016/j.cell.2010.06.011
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28-39; http://dx.doi.org/10.1038/nrc2559
   Google Scholar
• Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-25; PMID:12204532; http://dx.doi.org/10.1016/S1535-6108(02)00096-X
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242-9; PMID:17496200; http://dx.doi.org/10.1182/blood-2007-03-066936
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66:5790-7; PMID:16740718; http://dx.doi.org/10.1158/0008-5472.CAN-05-4187
   PubMed Web of Science ®Google Scholar
• Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood 2016; 127(15):1870-80; http://doi.org/10.1182/blood-2015-09-666214
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, et al. Ponatinib in refractory Philadelphia chromosome–positive leukemias. N Eng J Med 2012; 367:2075-88; PMID:23190221; http://dx.doi.org/10.1056/NEJMoa1205127
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9; PMID:2440339; http://dx.doi.org/10.1016/0003-2697(87)90021-2
   PubMed Web of Science ®Google Scholar
• Liedtke W, Battistini L, Brosnan CF, Raine CS. A comparison of methods for RNA extraction from lymphocytes for RT-PCR. PCR Methods Appl 1994; 4:185-7; PMID:7580904; http://dx.doi.org/10.1101/gr.4.3.185
   PubMedGoogle Scholar
• Asad S, Ijaz B, Ahmad W, Kausar H, Sarwar MT, Gull S, Shahid I, Khan MK, Hassan S. Development of persistent HCV genotype 3a infection cell culture model in huh-7 cell. Virol J 2012; 9:1; PMID:22214262; http://dx.doi.org/10.1186/1743-422X-9-11
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-37; PMID:15914554; http://dx.doi.org/10.1182/blood-2005-03-1036
   PubMed Web of Science ®Google Scholar
• Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109:5011-5; PMID:17303698; http://dx.doi.org/10.1182/blood-2006-01-015347
   PubMed Web of Science ®Google Scholar
• Iqbal Z AAM, Akhtar T, Khalid M, Aziz Z, Aleem Aamer, Gill Ammara T, Khalid Ahmad M, Alanazi Abdullah, Shah Ijaz H, Khalid Muhammad, Sabar Muhammad Farooq, Iqbal Mudassar. High frequencies of compound BCR-ABL mutations and their association with imatinib resistant, disease progression and late chronic phase disease in pakistani chronic myeloid leukemia patients necessitate the inclusion of molecular testing in routine clinical settings. Blood 2015; 126:5167.
   Web of Science ®Google Scholar
• Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Molecular and Cell Biol 2006; 26:6082-93; PMID:16880519; http://dx.doi.org/10.1128/MCB.02202-05
   PubMed Web of Science ®Google Scholar
• Kimura S, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 2014; 19:3-9; PMID:24258348; http://dx.doi.org/10.1007/s10147-013-0641-7
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica 2011; 96:918-24; PMID:21357704; http://dx.doi.org/10.3324/haematol.2010.039321
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. ASH Educ Program Book 2009; 2009:461-76; http://dx.doi.org/10.1182/asheducation-2009.1.461
   Google Scholar
• Trela E, Glowacki S, Błasiak J. Therapy of chronic myeloid Leukemia: twilight of the imatinib era? ISRN Oncol 2014; 2014:596483; PMID:24634785; http://dx.doi.org/10.1155/2014/596483
   PubMedGoogle Scholar
• Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118:1208-15; PMID:21562040; http://dx.doi.org/10.1182/blood-2010-12-326405
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23:4100-9; PMID:15867198; http://dx.doi.org/10.1200/JCO.2005.05.531
   PubMed Web of Science ®Google Scholar
• Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008; 26:4806-13; PMID:18645191; http://dx.doi.org/10.1200/JCO.2008.16.9953
   PubMed Web of Science ®Google Scholar
• Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcome. Leukemia Res 2014; 38:454-9; PMID:24456693; http://dx.doi.org/10.1016/j.leukres.2013.12.025
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358-63; PMID:18519952; http://dx.doi.org/10.1200/JCO.2007.15.8154
   PubMed Web of Science ®Google Scholar
• Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99:680-93; PMID:17470736; http://dx.doi.org/10.1093/jnci/djk150
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Lee FY, Müller M. Methods Of identifying and treating individuals exhibiting mutant Bcr/Abl kinase polypeptides. Google Patents 2007.
   Google Scholar
• Sawyers CL, Gorre ME, Shah NP, Nicoll J. Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571. Google Patents 2010
   Google Scholar
• Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-43; PMID:12654249; http://dx.doi.org/10.1016/S0092-8674(03)00190-9
   PubMed Web of Science ®Google Scholar
• Gorre M, Nicoll J, Sawyers C, Shah N. Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571. Google Patents 2002.
   Google Scholar
• Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R. BCR-ABLkinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcome. Leukemia Res 2014; 38:454-9; PMID:24456693; http://dx.doi.org/10.1016/j.leukres.2013.12.025
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, et al. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. Biomarker Res 2014; 2:6; PMID:24650752; http://dx.doi.org/10.1186/2050-7771-2-6
   PubMedGoogle Scholar
• Azam M, Latek RR, Daley GQ. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell 2003; 112:831-43; PMID:12654249; http://dx.doi.org/10.1016/S0092-8674(03)00190-9
   PubMed Web of Science ®Google Scholar
• Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I, Cimino G, Elia L, Lonetti A, Vignetti M, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011; 96:552-7; PMID:21193419; http://dx.doi.org/10.3324/haematol.2010.034173
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Gorre ME, Shah NP, Nicoll J. Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571. Google Patents 2014.
   Google Scholar